ERBB2 and neoplasm: In contrast, our studies of the T+P combination therapy demonstrate the synergistic activation of classical complement pathways, allowing for direct lysis (CDC) of HER2+ tumor cells and enhanced tumor phagocytosis (CDCP) by macrophages.